RxDoctor Payments Data

Akram Elgendy, MD

Cardiology · Gainesville, FLNPI 1437578218

Payments from drug & device makers

What this record shows

Edwards Lifesciences accounts for 61.4% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $1,803, more than ten times the $75 reported in 2022.

$4,707in general payments, 2019–2025

Across 54 payments — averaging $87.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$3K
  • Abbott$1K
  • Medtronic$152
  • E.r. Squibb & Sons, L.L.C.$122
  • Philips North America LLC$58
  • AstraZeneca$49
  • plus $194 from 7 others

What the payments were for

  • Travel & lodging$2,74958%
  • Food & beverage$1,95842%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,707 in reported general payments places this provider in the 75th percentile of 45 cardiology providers in Florida.

See all cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$120,764
Medicare patients
928
Services billed
1,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban167$163,197
EntrestoSacubitril/Valsartan114$127,311
JardianceEmpagliflozin63$60,885
XareltoRivaroxaban24$29,142
Repatha SureclickEvolocumab18$20,881
FarxigaDapagliflozin Propanediol22$18,358
BrilintaTicagrelor11$12,439
Repatha PushtronexEvolocumab11$6,522
Atorvastatin Calcium263$1,889
Ezetimibe80$1,859
Metoprolol Succinate216$1,359
Diltiazem 24hr Er (Cd)Diltiazem Hcl27$787
Flecainide Acetate11$587
Amlodipine Besylate112$539
Losartan Potassium72$522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$163,197167 claims
NovartisEntresto$32$127,311114 claims
AstraZenecaFarxiga, Brilinta$49$30,79733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 45 cardiology providers in Florida.

Other cardiology in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →